The appearance of troglitazone, a potent antidiabetic agent, marked a notable chapter in the management of type 2 diabetes. However, its removal from the market due to severe hepatotoxicity spurred broad investigation into related thiazolidinediones. Following pioglitazone and rosiglitazone emerged, offering akin mechanisms of action – primarily